查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108318

細胞療法市場分析及預測（至2035年）：按類型、產品、服務、技術、組件、應用、過程、最終用戶、解決方案和階段

Cell Therapy Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, End User, Solutions, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球細胞療法市場預計將從2025年的139億美元成長到2035年的614億美元，CAGR為15.9%。推動細胞療法市場成長的主要因素是先進細胞療法的日益普及和監管支持的加強。據美國食品藥物管理局（FDA）表示，FDA於2025年6月取消了所有已通過核准的BCMA和CD19靶向CAR-T細胞療法的風險評估和緩解策略（REMS）要求。這反映出人們對這些療法的安全性和臨床應用越來越有信心。監管流程的簡化有望改善患者獲得治療的機會，並促進細胞療法的更廣泛應用。

細胞療法市場依「類型」細分，包括自體、同種異體、異種、同基因及其他類型。其中，自體細胞療法憑藉其降低免疫排斥風險和提高患者相容性等優勢，佔了較大的市場佔有率。它廣泛應用於個人化醫療、腫瘤學和再生醫學領域。同種異體細胞療法由於其擴充性、供體來源細胞的易得性以及開發現成療法的潛力，正經歷著快速成長。異種細胞療法和同基因細胞療法主要用於特定研發領域。細胞工程、基因編輯和生產技術的快速發展，進一步推動了細胞療法解決方案的擴展。

市場區隔
類型 自體、同種異體、異種、同基因、其他
產品 幹細胞療法、非幹細胞療法、其他
服務 契約製造、細胞處理、細胞庫、其他
技術 體細胞技術、基因編輯技術、細胞永生化技術、細胞可塑性技術、其他
組件 細胞株、試劑/培養基、耗材、設備、其他
用途 腫瘤科、心血管疾病科、肌肉骨骼疾病科、神經系統疾病科、皮膚科、自體免疫疾病科、感染疾病、其他
過程 細胞增殖、細胞分離、細胞冷凍保存、細胞特性分析及其他應用。
最終用戶 醫院和診所、學術和研究機構、生物製藥公司、其他
解決方案 再生醫學、免疫療法、基因療法、其他
階段 臨床前、I期、II期、III期、商業化、其他

細胞療法市場的終端使用者包括醫院和診所、學術和研究機構、生物製藥公司等。生物製藥公司是主要的終端使用者群體，因為它們在細胞療法的研發、臨床試驗和先進療法的商業化方面投入巨大。醫院和診所擴大將細胞療法應用於腫瘤學、再生醫學和慢性病管理等領域。學術和研究機構透過在細胞生物學、疾病模型和治療方法發現方面的創新，為市場成長做出了貢獻。臨床試驗和法規核准的增加，以及研究機構與產業相關人員之間合作的加強，進一步推動了所有終端使用者群體對細胞療法的採用。

區域概覽

到2025年，北美佔據全球細胞療法市場最大佔有率，這主要得益於其先進的生物技術生態系統、強大的臨床研究基礎設施以及對再生醫學的大量投資。該地區匯聚了許多領先的生物技術和製藥公司，致力於開發用於治療腫瘤、血液疾病、自體免疫疾病和罕見遺傳疾病的自體和異體細胞療法。強力的政府資助、對先進治療藥物（ATMP）的有利監管流程以及眾多進行中的臨床試驗，加速創新細胞療法的商業化進程。此外，專業生產設施和合約研發生產機構（CDMO）的存在，以及CAR-T細胞療法的日益普及，進一步鞏固了北美在全球細胞療法市場的領先地位。

亞太地區預計將成為細胞療法市場成長最快的地區，這主要得益於生物技術和生物製藥行業的擴張、再生醫學投資的增加以及政府對先進治療研究的大力支持。中國、日本、韓國、印度和新加坡等國家正透過國家研究舉措、有利的監管改革以及符合GMP標準的生產設施的擴建，提升其細胞療法能力。癌症和慢性病盛行率的上升、臨床試驗活動的活性化以及個人化醫療的日益普及，進一步推動了市場擴張。此外，生物技術公司、學術機構和醫療服務提供者之間的策略合作，以及醫療基礎設施的改善和對細胞處理技術投資的增加，預計將使亞太地區在預測期內成為成長最快的區域市場。

主要趨勢和促進因素

擴大下一代細胞療法和同種異體移植平台的應用：

細胞療法市場正呈現強勁的趨勢，朝著開發新一代細胞療法邁進，包括同種異體預製療法、基因修飾免疫療法和基因修飾細胞產品。各公司正日益致力於提高細胞療法的可擴展性、生產效率和治療可及性，以克服傳統自體療法的限制。 CAR-T細胞工程、誘導多功能細胞（iPS細胞）和基因編輯等技術的進步，正將細胞療法的應用範圍從腫瘤學拓展至自體免疫疾病、心血管疾病和再生醫學等領域。此外，自動化細胞處理、冷凍保存和密封系統製造技術的創新，也提升了細胞療法的可靠性和商業性潛力。

對先進癌症治療和再生醫學的需求日益成長：

癌症發生率的上升和對先進再生醫學需求的不斷成長是細胞療法市場的主要促進因素。細胞療法，尤其是CAR-T療法，在治療骨髓惡性腫瘤方面展現出巨大的潛力，催生了對創新癌症治療方案的強勁需求。此外，幹細胞療法和再生醫學方法的研究進展日益擴大其應用範圍，使其涵蓋神經系統疾病、組織修復和免疫相關疾病等領域。製藥公司、生技公司和研究機構加大投資，以及細胞療法產品臨床試驗和法規核准的增加，加速市場成長。個人化醫療計劃的推進也進一步促進了細胞療法方案在全球範圍內的應用。

目錄

第1章 執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機會
  • 市場限制因素
  • 年複合成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 自體
    • 同種異體
    • 異種
    • 同基因
    • 其他
  • 市場規模及預測：依產品分類
    • 幹細胞療法
    • 非幹細胞療法
    • 其他
  • 市場規模及預測：依技術分類
    • 體細胞技術
    • 基因編輯技術
    • 細胞永生化技術
    • 細胞可塑性技術
    • 其他
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 心血管疾病
    • 肌肉骨骼疾病
    • 神經病變
    • 皮膚科
    • 自體免疫疾病
    • 感染疾病
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院和診所
    • 學術研究機構
    • 生物製藥公司
    • 其他
  • 市場規模及預測：依製程分類
    • 細胞增殖
    • 細胞分離
    • 細胞冷凍保存
    • 細胞表徵
    • 其他
  • 市場規模及預測：依服務分類
    • 契約製造
    • 細胞處理
    • 細胞庫
    • 其他
  • 市場規模及預測：依組件分類
    • 細胞株
    • 試劑和培養基
    • 消耗品
    • 裝置
    • 其他
  • 市場規模及預測：依階段分類
    • 臨床前階段
    • 第一階段
    • 第二階段
    • 第三階段
    • 商業化
    • 其他
  • 市場規模及預測：依解決方案分類
    • 再生醫學
    • 免疫療法
    • 基因治療
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要公司的策略

第8章 公司簡介

  • Novartis
  • Gilead Sciences
  • Bristol Myers Squibb
  • Bluebird Bio
  • Fate Therapeutics
  • Sangamo Therapeutics
  • Kite Pharma
  • Juno Therapeutics
  • Adaptimmune Therapeutics
  • Celgene
  • Allogene Therapeutics
  • CRISPR Therapeutics
  • Editas Medicine
  • Intellia Therapeutics
  • Cellectis
  • Bellicum Pharmaceuticals
  • Atara Biotherapeutics
  • Vericel Corporation
  • Athersys
  • Mesoblast

第9章 關於我們

簡介目錄
Product Code: GIS21212

The global Cell Therapy Market is projected to grow from $13.9 billion in 2025 to $61.4 billion by 2035, at a compound annual growth rate (CAGR) of 15.9%. The cell therapy market is driven by expanding adoption of advanced cellular therapies and increasing regulatory support. According to the U.S. Food and Drug Administration (FDA), in June 2025 the agency eliminated the Risk Evaluation and Mitigation Strategy (REMS) requirements for all approved BCMA- and CD19-directed CAR-T cell therapies, reflecting growing confidence in the safety and clinical use of these treatments. The streamlined regulatory pathway is expected to improve patient access and support broader adoption of cell therapies.

The Type segment of the Cell Therapy Market includes autologous, allogeneic, xenogeneic, syngeneic, and others. Among these, autologous cell therapy holds a significant market share due to its advantages, including reduced risk of immune rejection and improved patient compatibility. It is widely used in personalized medicine, oncology, and regenerative medicine applications. Allogeneic cell therapy is witnessing rapid growth due to its scalability, availability of donor-derived cells, and potential for developing off-the-shelf therapies. Xenogeneic and syngeneic approaches are primarily used in specialized research and therapeutic development applications. Increasing advancements in cell engineering, gene editing, and manufacturing technologies are further supporting the expansion of cell therapy solutions.

Market Segmentation
TypeAutologous, Allogeneic, Xenogeneic, Syngeneic, Others
ProductStem Cell Therapy, Non-Stem Cell Therapy, Others
ServicesContract Manufacturing, Cell Processing, Cell Banking, Others
TechnologySomatic Cell Technology, Gene Editing Technology, Cell Immortalization Technology, Cell Plasticity Technology, Others
ComponentCell Lines, Reagents and Media, Consumables, Equipment, Others
ApplicationOncology, Cardiovascular Diseases, Musculoskeletal Disorders, Neurological Disorders, Dermatology, Autoimmune Disorders, Infectious Diseases, Others
ProcessCell Expansion, Cell Isolation, Cell Cryopreservation, Cell Characterization, Others
End UserHospitals and Clinics, Academic and Research Institutes, Biopharmaceutical Companies, Others
SolutionsRegenerative Medicine, Immunotherapy, Gene Therapy, Others
StagePreclinical, Phase I, Phase II, Phase III, Commercialized, Others

The End User segment of the Cell Therapy Market includes hospitals and clinics, academic and research institutes, biopharmaceutical companies, and others. Biopharmaceutical companies represent a major end-user segment due to their significant investments in developing cell-based therapies, conducting clinical trials, and commercializing advanced treatments. Hospitals and clinics are increasingly adopting cell therapies for oncology, regenerative medicine, and chronic disease management applications. Academic and research institutes contribute to market growth through innovations in cell biology, disease modeling, and therapeutic discovery. The increasing number of clinical trials, regulatory approvals, and collaborations between research organizations and industry players are further driving adoption across end-user segments.

Geographical Overview

North America held the largest share of the global cell therapy market in 2025, driven by its advanced biotechnology ecosystem, robust clinical research infrastructure, and significant investments in regenerative medicine. The region is home to leading biotechnology and pharmaceutical companies developing autologous and allogeneic cell therapies for oncology, hematological disorders, autoimmune diseases, and rare genetic conditions. Strong government funding, favorable regulatory pathways for advanced therapy medicinal products (ATMPs), and a high number of ongoing clinical trials have accelerated the commercialization of innovative cell therapies. Additionally, the presence of specialized manufacturing facilities, contract development and manufacturing organizations (CDMOs), and increasing adoption of CAR-T cell therapies continue to reinforce North America's leadership in the global cell therapy market.

Asia Pacific is expected to witness the highest growth in the cell therapy market due to expanding biotechnology and biopharmaceutical industries, increasing investments in regenerative medicine, and growing government support for advanced therapeutic research. Countries such as China, Japan, South Korea, India, and Singapore are strengthening their cell therapy capabilities through national research initiatives, favorable regulatory reforms, and expanding GMP-compliant manufacturing facilities. Rising prevalence of cancer and chronic diseases, increasing clinical trial activity, and growing adoption of personalized medicine are further driving market expansion. Moreover, strategic collaborations between biotechnology companies, academic institutions, and healthcare providers, coupled with improving healthcare infrastructure and rising investments in cell processing technologies, are expected to position Asia Pacific as the fastest-growing regional market during the forecast period.

Key Trends and Drivers

Increasing Adoption of Next-Generation Cell Therapies and Allogeneic Platforms:

The Cell Therapy Market is witnessing a strong trend toward the development of next-generation cell therapies, including allogeneic off-the-shelf treatments, engineered immune cell therapies, and gene-modified cell products. Companies are increasingly focusing on improving scalability, manufacturing efficiency, and treatment accessibility by overcoming limitations associated with traditional autologous therapies. Advances in technologies such as CAR-T cell engineering, induced pluripotent stem cells (iPSCs), and gene editing are expanding applications beyond oncology into autoimmune disorders, cardiovascular diseases, and regenerative medicine. Additionally, innovations in automated cell processing, cryopreservation, and closed-system manufacturing are enhancing the reliability and commercial potential of cell-based therapies.

Growing Demand for Advanced Cancer Treatments and Regenerative Medicine:

The rising prevalence of cancer and the increasing demand for advanced regenerative therapies are major drivers of the Cell Therapy Market. Cell-based treatments, particularly CAR-T therapies, have demonstrated significant potential in treating hematological malignancies, creating strong demand for innovative oncology solutions. Furthermore, increasing research into stem cell therapies and regenerative approaches is expanding applications across neurological disorders, tissue repair, and immune-related diseases. Growing investments from pharmaceutical companies, biotechnology firms, and research institutions, along with increasing clinical trials and regulatory approvals for cell-based products, are accelerating market growth. The expansion of personalized medicine initiatives is further supporting the adoption of cell therapy solutions worldwide.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Services
  • 2.8 Key Market Highlights by Component
  • 2.9 Key Market Highlights by Stage
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Autologous
    • 4.1.2 Allogeneic
    • 4.1.3 Xenogeneic
    • 4.1.4 Syngeneic
    • 4.1.5 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Stem Cell Therapy
    • 4.2.2 Non-Stem Cell Therapy
    • 4.2.3 Others
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Somatic Cell Technology
    • 4.3.2 Gene Editing Technology
    • 4.3.3 Cell Immortalization Technology
    • 4.3.4 Cell Plasticity Technology
    • 4.3.5 Others
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Oncology
    • 4.4.2 Cardiovascular Diseases
    • 4.4.3 Musculoskeletal Disorders
    • 4.4.4 Neurological Disorders
    • 4.4.5 Dermatology
    • 4.4.6 Autoimmune Disorders
    • 4.4.7 Infectious Diseases
    • 4.4.8 Others
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals and Clinics
    • 4.5.2 Academic and Research Institutes
    • 4.5.3 Biopharmaceutical Companies
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 Cell Expansion
    • 4.6.2 Cell Isolation
    • 4.6.3 Cell Cryopreservation
    • 4.6.4 Cell Characterization
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Services (2020-2035)
    • 4.7.1 Contract Manufacturing
    • 4.7.2 Cell Processing
    • 4.7.3 Cell Banking
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Component (2020-2035)
    • 4.8.1 Cell Lines
    • 4.8.2 Reagents and Media
    • 4.8.3 Consumables
    • 4.8.4 Equipment
    • 4.8.5 Others
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Preclinical
    • 4.9.2 Phase I
    • 4.9.3 Phase II
    • 4.9.4 Phase III
    • 4.9.5 Commercialized
    • 4.9.6 Others
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Regenerative Medicine
    • 4.10.2 Immunotherapy
    • 4.10.3 Gene Therapy
    • 4.10.4 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Process
      • 5.2.1.7 Services
      • 5.2.1.8 Component
      • 5.2.1.9 Stage
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Process
      • 5.2.2.7 Services
      • 5.2.2.8 Component
      • 5.2.2.9 Stage
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Process
      • 5.2.3.7 Services
      • 5.2.3.8 Component
      • 5.2.3.9 Stage
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Process
      • 5.3.1.7 Services
      • 5.3.1.8 Component
      • 5.3.1.9 Stage
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Process
      • 5.3.2.7 Services
      • 5.3.2.8 Component
      • 5.3.2.9 Stage
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Process
      • 5.3.3.7 Services
      • 5.3.3.8 Component
      • 5.3.3.9 Stage
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Process
      • 5.4.1.7 Services
      • 5.4.1.8 Component
      • 5.4.1.9 Stage
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Process
      • 5.4.2.7 Services
      • 5.4.2.8 Component
      • 5.4.2.9 Stage
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Process
      • 5.4.3.7 Services
      • 5.4.3.8 Component
      • 5.4.3.9 Stage
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Process
      • 5.4.4.7 Services
      • 5.4.4.8 Component
      • 5.4.4.9 Stage
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Process
      • 5.4.5.7 Services
      • 5.4.5.8 Component
      • 5.4.5.9 Stage
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Process
      • 5.4.6.7 Services
      • 5.4.6.8 Component
      • 5.4.6.9 Stage
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Process
      • 5.4.7.7 Services
      • 5.4.7.8 Component
      • 5.4.7.9 Stage
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Process
      • 5.5.1.7 Services
      • 5.5.1.8 Component
      • 5.5.1.9 Stage
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Process
      • 5.5.2.7 Services
      • 5.5.2.8 Component
      • 5.5.2.9 Stage
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Process
      • 5.5.3.7 Services
      • 5.5.3.8 Component
      • 5.5.3.9 Stage
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Process
      • 5.5.4.7 Services
      • 5.5.4.8 Component
      • 5.5.4.9 Stage
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Process
      • 5.5.5.7 Services
      • 5.5.5.8 Component
      • 5.5.5.9 Stage
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Process
      • 5.5.6.7 Services
      • 5.5.6.8 Component
      • 5.5.6.9 Stage
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Process
      • 5.6.1.7 Services
      • 5.6.1.8 Component
      • 5.6.1.9 Stage
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Process
      • 5.6.2.7 Services
      • 5.6.2.8 Component
      • 5.6.2.9 Stage
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Process
      • 5.6.3.7 Services
      • 5.6.3.8 Component
      • 5.6.3.9 Stage
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Process
      • 5.6.4.7 Services
      • 5.6.4.8 Component
      • 5.6.4.9 Stage
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Process
      • 5.6.5.7 Services
      • 5.6.5.8 Component
      • 5.6.5.9 Stage
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Novartis
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Gilead Sciences
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Bristol Myers Squibb
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Bluebird Bio
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Fate Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Sangamo Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Kite Pharma
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Juno Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Adaptimmune Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Celgene
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Allogene Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 CRISPR Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Editas Medicine
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Intellia Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Cellectis
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Bellicum Pharmaceuticals
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Atara Biotherapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Vericel Corporation
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Athersys
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Mesoblast
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us